• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Evelo Biosciences Announces Reverse Stock Split Effective

    6/29/23 9:00:00 AM ET
    $EVLO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EVLO alert in real time by email

    – EVLO common stock expected to begin trading on a split-adjusted basis on June 30, 2023 –

    CAMBRIDGE, Mass., June 29, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company's common stock. The reverse stock split will become effective at 5:00 p.m. Eastern Time today, June 29, 2023, after close of trading on The Nasdaq Global Select Market. The Company's common stock is expected to commence trading on a split-adjusted basis when the markets open on June 30, 2023 under the existing trading symbol "EVLO." The new CUSIP number for the Company's common stock following the reverse stock split will be 299734 202.

    The primary goal of the reverse stock split is to increase the per share market price of the Company's common stock to meet the minimum per share bid price requirement for continued listing on The Nasdaq Global Select Market. The reverse stock split was approved by the Company's stockholders at its annual meeting of stockholders held on June 8, 2023. On June 27, 2023, following the annual meeting, the Company's Board of Directors approved the reverse stock split at the ratio of 1-for-20.

    As a result of the reverse stock split, every 20 shares of the Company's common stock issued and outstanding will be automatically reclassified into one new share of the Company's common stock. Proportionate adjustments will be made to the exercise prices and the number of shares underlying the Company's outstanding equity awards, as applicable, and warrants exercisable for shares of common stock, as well as to the number of shares issuable under the Company's equity incentive plans and certain existing agreements. The common stock issued pursuant to the reverse stock split will remain fully paid and non-assessable. The reverse stock split will not affect the number of authorized shares of common stock or the par value of the common stock.

    No fractional shares will be issued in connection with the reverse stock split. Stockholders who would otherwise be entitled to receive fractional shares as a result of the reverse stock split will be entitled to a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled multiplied by the closing sales price per share of the common stock (as adjusted to give effect to the reverse stock split) on The Nasdaq Global Select Market today, the last trading day immediately preceding the effective time of the reverse stock split.

    American Stock Transfer & Trust Company, LLC ("AST"), the Company's transfer agent, is acting as the exchange agent for the reverse stock split. Stockholders with book-entry shares or who hold their shares through a bank, broker or other nominee will not need to take any action. Stockholders of record holding certificates representing pre-split shares of the Company's common stock, as applicable, will receive a letter of transmittal from AST with instructions on how to surrender certificates representing pre-split shares. Stockholders should not send in their pre-split certificates until they receive a letter of transmittal from AST. Stockholders of record who held pre-split certificates will receive their post-split shares book-entry and will be receiving a statement from AST regarding their common stock ownership post-reverse stock split.

    Additional information about the reverse stock split can be found in the Company's definitive proxy statement (the "Proxy Statement") filed with the Securities and Exchange Commission (the "SEC") on April 28, 2023, which is available free of charge at the SEC's website, www.sec.gov, and on the Company's website at www.evelobio.com.

    About Evelo Biosciences

    Evelo Biosciences is a clinical stage biotechnology company developing a novel platform of orally delivered anti-inflammatory medicines acting on the small intestinal axis, SINTAX, with systemic therapeutic effects. The small intestine plays a central role in governing inflammation throughout the body. The Company's product candidates are pharmaceutical preparations of single strains of microbes or their extracellular vesicles (EVs). Evelo's vision is to create therapies that are effective, safe, well-tolerated, and affordable to improve the lives of the billions of people living with inflammatory diseases. If shown to be effective in inflammatory disease mediated by the Th1, Th2 or Th17 inflammatory pathways, these same investigational medicines could be effective in additional inflammatory diseases, such as psoriatic and other forms of arthritis, asthma, allergy, and inflammatory bowel disease.

    For more information, please visit www.evelobio.com

    Forward Looking Statements

    This press release contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements concerning the expected timing of the reverse stock split, the impact of the reverse stock split on the Company's share price, and the Company's ability to meet the minimum per share bid price requirement for continued listing on The Nasdaq Global Select Market.

    These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the potential volatility of our common stock; and the potential delisting of our common stock from The Nasdaq Global Select Market. These and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q for the three months ended March 31, 2023, and our other reports filed with the U.S. Securities and Exchange Commission, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

    Contacts

    Investors:

    [email protected]

    Media:

    [email protected]



    Primary Logo

    Get the next $EVLO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EVLO

    DatePrice TargetRatingAnalyst
    11/2/2021$44.00 → $41.50Market Outperform
    JMP Securities
    11/1/2021$12.00Neutral → Buy
    Chardan Capital Markets
    6/23/2021$36.00 → $38.00Market Outperform
    JMP Securities
    6/23/2021$28.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $EVLO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alltrna Announces Updates to Its Board of Directors

      Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera

      7/17/24 8:00:00 AM ET
      $APRE
      $CYTK
      $EVLO
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights

      – EDP2939 Phase 2 trial in moderate psoriasis fully enrolled with topline data expected early Q4 2023– Completed $25.5 Million Private Placement– Restructured and reduced secured debt with Horizon Technology Finance Corporation CAMBRIDGE, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), ("Evelo" or the "Company") a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announced its second quarter 2023 financial results and recent business highlights. Simba Gill, Ph.D., Evelo's Chief Executive Officer, said, "We are on track for a top line read

      8/14/23 7:30:00 AM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evelo Biosciences Closes $25.5 Million Private Placement

      Restructures and reduces secured debt with Horizon Technology Finance Corporation Appoints two new members and decreases size of Board of Directors CAMBRIDGE, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO) (the "Company" or "Evelo"), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announces that it closed the previously announced private placement, resulting in gross proceeds of approximately $25.5 million from the sale of 11,025,334 shares of its common stock at a purchase price of $2.31 per share. The offering was led by Evelo's fo

      7/12/23 7:30:00 AM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVLO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Bodmer Mark converted options into 6,625 shares and sold $1,044 worth of shares (3,163 units at $0.33), increasing direct ownership by 16% to 25,732 units (SEC Form 4)

      4 - Evelo Biosciences, Inc. (0001694665) (Issuer)

      11/8/23 8:32:53 PM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mchale Duncan converted options into 6,500 shares and sold $1,024 worth of shares (3,103 units at $0.33), increasing direct ownership by 25% to 16,984 units (SEC Form 4)

      4 - Evelo Biosciences, Inc. (0001694665) (Issuer)

      11/8/23 8:32:28 PM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gill Simba sold $57 worth of shares (172 units at $0.33) and converted options into 1,172 shares, increasing direct ownership by 6% to 17,758 units (SEC Form 4)

      4 - Evelo Biosciences, Inc. (0001694665) (Issuer)

      11/8/23 8:31:56 PM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVLO
    Financials

    Live finance-specific insights

    See more
    • Evelo Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022

      CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 24, 2022 to report its fourth quarter and full year 2021 financial results and discuss business highlights. To access the live conference call, please dial 866-795-3242 (domestic) or 409-937-8909 (international) and refer to conference ID 6076311. A live webcast of the event will also be available under "News and Events" in the Investors section of Eve

      3/17/22 7:00:00 AM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evelo Biosciences to Report Third Quarter 2021 Financial Results on Thursday, October 28, 2021

      CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, October 28, 2021, to report its third quarter 2021 financial results and discuss business highlights. To access the live conference call, please dial 866-795-3242 (domestic) or 409-937-8909 (international) and refer to conference ID 7574834. A live webcast of the event will also be available under "News and Events" in the Investors section of Evelo's website at h

      10/21/21 7:00:00 AM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evelo Biosciences to Report Second Quarter 2021 Financial Results on Thursday, July 29, 2021

      CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (NASDAQ:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, July 29, 2021, to report its second quarter 2021 financial results and discuss business highlights. To access the live conference call, please dial 866-795-3242 (domestic) or 409-937-8909 (international) and refer to conference ID 1658301. A live webcast of the event will also be available under "News and Events" in the Investors section of Evelo's website at http://ir.evelobio.com. The archived webcast will be ava

      7/22/21 7:00:00 AM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVLO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $EVLO
    SEC Filings

    See more

    $EVLO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form SC 13G/A filed by Evelo Biosciences Inc. (Amendment)

      SC 13G/A - Evelo Biosciences, Inc. (0001694665) (Subject)

      12/11/23 9:09:54 AM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Evelo Biosciences Inc. (Amendment)

      SC 13G/A - Evelo Biosciences, Inc. (0001694665) (Subject)

      11/13/23 9:02:39 AM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Evelo Biosciences Inc.

      SC 13G - Evelo Biosciences, Inc. (0001694665) (Subject)

      8/10/23 8:19:47 AM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Evelo Biosciences Inc.

      EFFECT - Evelo Biosciences, Inc. (0001694665) (Filer)

      3/11/24 12:15:15 AM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15-12G filed by Evelo Biosciences Inc.

      15-12G - Evelo Biosciences, Inc. (0001694665) (Filer)

      1/26/24 5:30:25 PM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Evelo Biosciences Inc.

      S-8 POS - Evelo Biosciences, Inc. (0001694665) (Filer)

      1/26/24 5:29:48 PM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities reiterated coverage on Evelo Biosciences with a new price target

      JMP Securities reiterated coverage of Evelo Biosciences with a rating of Market Outperform and set a new price target of $41.50 from $44.00 previously

      11/2/21 7:54:09 AM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evelo Biosciences upgraded by Chardan Capital Markets with a new price target

      Chardan Capital Markets upgraded Evelo Biosciences from Neutral to Buy and set a new price target of $12.00

      11/1/21 8:36:16 AM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities reiterated coverage on Evelo Biosciences with a new price target

      JMP Securities reiterated coverage of Evelo Biosciences with a rating of Market Outperform and set a new price target of $38.00 from $36.00 previously

      6/23/21 1:58:41 PM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVLO
    Leadership Updates

    Live Leadership Updates

    See more
    • Alltrna Announces Updates to Its Board of Directors

      Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera

      7/17/24 8:00:00 AM ET
      $APRE
      $CYTK
      $EVLO
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Evelo Biosciences Closes $25.5 Million Private Placement

      Restructures and reduces secured debt with Horizon Technology Finance Corporation Appoints two new members and decreases size of Board of Directors CAMBRIDGE, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO) (the "Company" or "Evelo"), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announces that it closed the previously announced private placement, resulting in gross proceeds of approximately $25.5 million from the sale of 11,025,334 shares of its common stock at a purchase price of $2.31 per share. The offering was led by Evelo's fo

      7/12/23 7:30:00 AM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellarity Appoints Dr. Gregory J. Moore to Board of Directors

      Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the appointment of Gregory J. Moore, M.D., Ph.D., to the Company's Board of Directors. As the former Corporate Vice President for Microsoft, leading global health and life sciences, Dr. Moore brings extensive experience and expertise in integrating R&D, AI and machine learning, and cloud and data technologies to positively transform companies within the health and life sciences ecosystem. "Greg is an industry leader, driving technology and life sciences innovation at the intersection of medical and large-scale computation," said Stephen Berenson, Chairman of Cellar

      6/6/23 8:00:00 AM ET
      $DNLI
      $DVA
      $EVLO
      $FHTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Misc Health and Biotechnology Services
      Biotechnology: Pharmaceutical Preparations